192 related articles for article (PubMed ID: 10584132)
1. [Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
Momm F; Bechtold C; Fischer K; Tsekos A; Henke M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():2-5. PubMed ID: 10584132
[TBL] [Abstract][Full Text] [Related]
2. Alteration of radiation-induced hematotoxicity by amifostine.
Momm F; Bechtold C; Rudat V; Strnad V; Tsekos A; Fischer K; Henke M
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):947-51. PubMed ID: 11704315
[TBL] [Abstract][Full Text] [Related]
3. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
4. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
5. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
6. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
9. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
10. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
12. Moist skin care can diminish acute radiation-induced skin toxicity.
Momm F; Weissenberger C; Bartelt S; Henke M
Strahlenther Onkol; 2003 Oct; 179(10):708-12. PubMed ID: 14566480
[TBL] [Abstract][Full Text] [Related]
13. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
14. Amifostine--a radioprotector in locally advanced head and neck tumors.
Schönekäs KG; Wagner W; Prott FJ
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
16. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
Koukourakis GV; Baksevanis CN; Zambatis H; Gritzapis A; Maltezos E; Simopoulos C; Koukourakis MI
Int J Radiat Biol; 2009 Jan; 85(1):96-104. PubMed ID: 19205988
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
18. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Peters K; Mücke R; Hamann D; Ziegler PG; Fietkau R
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():23-6. PubMed ID: 10584136
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
Bardet E; Martin L; Calais G; Alfonsi M; Feham NE; Tuchais C; Boisselier P; Dessard-Diana B; Seng SH; Garaud P; Aupérin A; Bourhis J
J Clin Oncol; 2011 Jan; 29(2):127-33. PubMed ID: 21115863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
